-
Q3 2023 Earnings Season: Record Revenue, Robust Performance, Consistent Results From Three Cannabis Companies
Thursday, November 9, 2023 - 10:47pm | 879Read More...Nova Cannabis Inc. Reports Record Q3 2023 Revenue, Achieving Gross Margin Growth Nova Cannabis Inc. (TSX: NOVC) (OTCQB: NVACF) released its unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2023. Q3 Financial Highlights Total...
-
Indivior Positioned To Profit If Aelis Farma's Study Of Cannabis Use Disorder Succeeds
Wednesday, June 1, 2022 - 12:48pm | 446Read More...Indivior PLC (OTCPK:INVVY) (LON:INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after Indivior and Aelis Farma announced a strategic collaboration that includes an exclusive option...
-
Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users
Monday, April 11, 2022 - 10:34am | 498Read More...Indivior PLC (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid, to better understand how buprenorphine can reduce fentanyl-induced respiratory depression....
